公开(公告)号：US20220112287A1

公开(公告)日：2022-04-14

申请号：US17559935

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Jenny Jianlin CHEN ,  Tahamtan AHMADI ,  Christopher W.L. CHIU ,  Esther C.W. BREIJ ,  Ida HIEMSTRA ,  Maria N. JURE-KUNKEL

IPC: C07K16/28

Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.

公开(公告)号：US11858995B2

公开(公告)日：2024-01-02

申请号：US17559935

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Jenny Jianlin Chen ,  Tahamtan Ahmadi ,  Christopher W. L. Chiu ,  Esther C. W. Breij ,  Ida Hiemstra ,  Maria N. Jure-Kunkel

IPC: A61K39/00 ,  C07K16/28

CPC classification number: C07K16/2809 ,  C07K16/2887 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/31

Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.

公开(公告)号：US20220119544A1

公开(公告)日：2022-04-21

申请号：US17558430

申请日：2021-12-21

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Tahamtan AHMADI ,  Christopher W.L. CHIU ,  Esther C.W BREIJ ,  Ida HIEMSTRA ,  Maria N. JURE-KUNKEL

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/675 ,  A61K39/395 ,  A61K31/704 ,  A61K31/475 ,  A61K31/573

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

公开(公告)号：US20220112301A1

公开(公告)日：2022-04-14

申请号：US17560006

申请日：2021-12-22

Applicant: Genmab A/S

Inventor： Brian Elliott ,  Tahamtan Ahmadi

IPC: C07K16/28 ,  A61K31/573 ,  A61K31/7072 ,  A61P35/00 ,  A61K31/555

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).

公开(公告)号：US11845805B2

公开(公告)日：2023-12-19

申请号：US17558430

申请日：2021-12-21

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Tahamtan Ahmadi ,  Christopher W. L. Chiu ,  Esther C. W Breij ,  Ida Hiemstra ,  Maria N. Jure-Kunkel

IPC: A61P35/00 ,  A61K31/475 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  C07K16/28 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2887 ,  A61K31/475 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61K39/3955 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

公开(公告)号：US11535679B2

公开(公告)日：2022-12-27

申请号：US17558404

申请日：2021-12-21

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Tahamtan Ahmadi ,  Christopher W. L. Chiu ,  Esther C. W. Breij

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/4184 ,  A61K39/00

Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.

公开(公告)号：US11608383B2

公开(公告)日：2023-03-21

申请号：US17559938

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Tahamtan Ahmadi ,  Christopher W. L. Chiu ,  Esther C. W. Breij ,  Ida Hiemstra ,  Maria N. Jure-Kunkel

IPC: A61K39/40 ,  A61K39/395 ,  C07K16/28 ,  A61K31/454 ,  C07K16/00

Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.

公开(公告)号：US11548952B2

公开(公告)日：2023-01-10

申请号：US17560006

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Tahamtan Ahmadi

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/555 ,  A61K31/573 ,  A61K31/7072

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).